TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8042458

Group type: EXPERIMENTAL
Intervention: Warm tub bath
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (no bath)
Number of subjects: 110
Study: 2898622

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29898210

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 144
Study: 28570723

Group type: EXPERIMENTAL
Intervention: Oral X-82 (50 mg alternate days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral X-82 (50 mg daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral X-82 (100 mg alternate days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral X-82 (100 mg daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral X-82 (200 mg daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral X-82 (300 mg daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral X-82 (all doses)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Adverse events attributed to X-82
Number of subjects: 35
Study: 25065017

Group type: EXPERIMENTAL
Intervention: Family-aided Assertive Community Treatment (FACT)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Community care
Number of subjects: 337
Study: 23278647

Group type: EXPERIMENTAL
Intervention: Surinabant 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Surinabant 60 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Surinabant 5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21263322

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Noisy pressure support ventilation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pressure-controlled ventilation
Number of subjects: 24
Study: 18422764

Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg twice daily
Number of subjects: 4172
Study: 16968508

Group type: EXPERIMENTAL
Intervention: Push-and-pull enteroscopy (PPE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Push enteroscopy (PE)
Number of subjects: 52
Study: 14502133

Group type: EXPERIMENTAL
Intervention: Hypothermic circulatory arrest plus retrograde cerebral perfusion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Hypothermic circulatory arrest alone
Number of subjects: 38
Study: 10783347

Group type: EXPERIMENTAL
Intervention: Follicular fluid IL-6 concentrations at the time of oocyte retrieval
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Serum IL-8 concentrations at the time of embryo transfer
Number of subjects: 156

Group type: COMPARATOR
Intervention: Serum TNF-alpha concentrations
Number of subjects: 156

Group type: COMPARATOR
Intervention: Serum VEGF concentrations
Number of subjects: 156
Study: 9349067

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg with droperidol 0.75 mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg with droperidol 1.25 mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 94
Study: 8455964

Group type: EXPERIMENTAL
Intervention: Outpatient group cognitive therapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cognitive therapy in combination with relaxation training
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waiting-list (WL) control condition
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All treatment conditions (including WL)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 102
Study: 3816293

Group type: EXPERIMENTAL
Intervention: Mequitazine (5 mg twice daily for 14 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 30
Study: 29727370

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control (no intra-aortic balloon pump)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Meta-analysis of 11 randomized controlled trials
Number of subjects: 181
Study: 26886637

Group type: EXPERIMENTAL
Intervention: PMC-PEG-DP
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: PMC-NaP-DP
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: PMC-PEG-SD
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: PMC-NaP-SD
Number of subjects: 236
Study: 24886228

Group type: EXPERIMENTAL
Intervention: Questionnaire assessing confidence and knowledge in managing CKD
Number of subjects: 78
Study: 22584638

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rocuronium (0.9 mg/kg)
Number of subjects: 80
Study: 20215699

Group type: EXPERIMENTAL
Intervention: Ad2HIF (hypoxia inducible factor-1alpha)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 13
Study: 17367953

Group type: EXPERIMENTAL
Intervention: Manual-guided group behavioral therapies (Cognitive Behavioral Therapy or Twelve Step Facilitation)
Number of subjects: 78
Study: 16276167

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for > or = 8 hrs a day in the first 48 hrs
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 97
Study: 12003439

Group type: EXPERIMENTAL
Intervention: Elk velvet antler (2 capsules, 215 mg each)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Elk velvet antler (4 capsules, 215 mg each)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Elk velvet antler (6 capsules, 215 mg each)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9705684

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 10948

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10948
Study: 7614523

Group type: EXPERIMENTAL
Intervention: Naproxen, 500 mg twice daily
Number of subjects: 99

Group type: COMPARATOR
Intervention: Nabumetone, 1,000 mg once daily
Number of subjects: 99
Study: 2203262

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg in the morning and 250 mg in the evening
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulindac 200 mg twice a day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 10
Study: 1194473

Group type: EXPERIMENTAL
Intervention: Transactional analysis program (O.H. Close School)
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Behavior modification program (Karl Holton School)
Number of subjects: 983

Group type: COMPARATOR
Intervention: Both programs
Number of subjects: 983
Study: 31948665

Group type: EXPERIMENTAL
Intervention: Hybrid group (routine electrophysiological confirmation and additional catheter ablation after totally thoracoscopic ablation)
Number of subjects: 45

Group type: COMPARATOR
Intervention: TTA group (no routine electrophysiological confirmation)
Number of subjects: 45

Group type: COMPARATOR
Intervention: TTA group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hybrid group
Number of subjects: 45
Study: 30630649

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 1181

Group type: COMPARATOR
Intervention: Pooled CEA and CAS
Number of subjects: 1181
Study: 29231431

Group type: EXPERIMENTAL
Intervention: Micro-invasive embedding combined with montelukast sodium
Number of subjects: 240

Group type: COMPARATOR
Intervention: Montelukast sodium (5 mg once daily for 3 months)
Number of subjects: 240
Study: 25169119

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT) - cisplatin and 5-fluorouracil with 45 Gy of concurrent radiotherapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Perioperative chemotherapy (PCT) - docetaxel, cisplatin, 5-FU
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Perioperative chemotherapy (PCT)
Number of subjects: 116
Study: 22774852

Group type: EXPERIMENTAL
Intervention: Retrieval practice (testing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subsequent restudy opportunity
Number of subjects: 0
Study: 21493739

Group type: EXPERIMENTAL
Intervention: Warfarin (low-intensity monitored-dose, target INR 1.5 to 1.9)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 18218827

Group type: EXPERIMENTAL
Intervention: High-resistance exercise (HR group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Low-resistance exercise (LR group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 102
Study: 16763086

Group type: EXPERIMENTAL
Intervention: New antimicrobial and fluoride-releasing self-etching primer (Clearfil Protect Bond) used according to manufacturer's recommendations
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: New antimicrobial and fluoride-releasing self-etching primer (Clearfil Protect Bond) used without prior etching
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional bonding procedure (etching, Transbond XT)
Number of subjects: 120
Study: 14690568

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 + NS 100 ml or 200 ml (Group A)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 + Cisplatin 30 mg/m2 (Group B)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Imported Gemzar + Cisplatin 30 mg/m2 (Group C)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2 (Group B)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Hematological toxicity (Groups B and C)
Number of subjects: 124
Study: 10768309

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at a mean dosage of 29 mg/kg/day, maximum dosage of 50 mg/kg/day, for a mean duration of 18 months.
Number of subjects: 11
Study: 8614073

Group type: EXPERIMENTAL
Intervention: Cryopreserved cultured epidermal allografts (CEAs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 16
Study: 1293910

Group type: EXPERIMENTAL
Intervention: VAD regimen (vincristine, doxorubicin, dexamethasone)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Dexamethasone (D)
Number of subjects: 56
Study: 6376485

Group type: EXPERIMENTAL
Intervention: Isocarboxazid (40-50 mg/day)
Number of subjects: 0
Study: 31218759

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Observer-based rating scale for skills assessment (SAPH)
Number of subjects: 66
Study: 28941006

Group type: EXPERIMENTAL
Intervention: 5 μg/kg palonosetron
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: 10 μg/kg palonosetron
Number of subjects: 565

Group type: COMPARATOR
Intervention: 3 × 150 μg/kg ondansetron
Number of subjects: 565
Study: 27163805

Group type: EXPERIMENTAL
Intervention: Bapineuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24447683

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 120

Group type: COMPARATOR
Intervention: α-glucosidase inhibitor (αGI)
Number of subjects: 120
Study: 22316445

Group type: EXPERIMENTAL
Intervention: Tai chi
Number of subjects: 195
Study: 20395612

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA for 20 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tDCS (for 20 minutes)
Number of subjects: 10
Study: 16394780

Group type: EXPERIMENTAL
Intervention: Ventilatory strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group participants
Number of subjects: 0
Study: 12679451

Group type: EXPERIMENTAL
Intervention: Total estradiol
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Bioavailable estradiol
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Bioavailable testosterone
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Bioavailable estradiol (after adjusting for body mass index and WHR)
Number of subjects: 845
Study: 10720847

Group type: EXPERIMENTAL
Intervention: Laparoscopic procedures (nephrectomy, renal cyst marsupialization, varix ligation)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Open unilateral nephrectomy
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Laparoscopic procedures (including ESWL and minor procedures)
Number of subjects: 145
Study: 9113940

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg once daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1410072

Group type: EXPERIMENTAL
Intervention: Broad spectrum fluorescent light
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cool white light
Number of subjects: 11
Study: 3890504

Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg orally every 6 hours
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30044959

Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord-derived mesenchymal stem cells (MSCs) at doses of 1 × 10^6 cells/kg, 2 × 10^6 cells/kg, and 3 × 10^6 cells/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord-derived mesenchymal stem cells (MSCs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Historical case-matched comparison group
Number of subjects: 15
Study: 26656140

Group type: EXPERIMENTAL
Intervention: Model including self-reported socioeconomic, health status, and psychosocial characteristics
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Model incorporating only clinical and demographic factors
Number of subjects: 1004
Study: 24553557

Group type: EXPERIMENTAL
Intervention: Brief alcohol interventions in Study 1
Number of subjects: 2089

Group type: EXPERIMENTAL
Intervention: Brief alcohol interventions in Study 2
Number of subjects: 2089
Study: 22289995

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HD-DXM) 40 mg/day for 4 consecutive days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pretherapy patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HD-DXM)
Number of subjects: 25
Study: 20216531

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment targeting parents' responses and children's coping (3 sessions)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Educational intervention (3 sessions)
Number of subjects: 200
Study: 17353100

Group type: EXPERIMENTAL
Intervention: Concomitant (escape and avoidance) schedules of reinforcement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other operant schedules (not specified)
Number of subjects: 0
Study: 16555797

Group type: EXPERIMENTAL
Intervention: Nutrition labeling on restaurant menus
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Value size pricing
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Nutrition importance
Number of subjects: 79
Study: 12570912

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy at an initial dose of 0.125 IU/Kg/week followed by 0.250 IU/Kg/week
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 12212211

Group type: EXPERIMENTAL
Intervention: Full-dose aprotinin (Group A, n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pump-prime-only aprotinin (Group B, n = 10)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (Group C, n = 9)
Number of subjects: 29
Study: 8808995

Group type: EXPERIMENTAL
Intervention: Water Exercisers (WE)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Land Exercisers (LE)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Water Sitters (WS)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Land Sitters (LS)
Number of subjects: 4
Study: 1390529

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of cefuroxime (125 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subconjunctival injection of both cefuroxime and Betnesol (betamethasone sodium phosphate 0.1%)
Number of subjects: 20
Study: 4056964

Group type: EXPERIMENTAL
Intervention: Restrictive diets based on oral food challenge results
Number of subjects: 113

Group type: COMPARATOR
Intervention: Double-blind placebo-controlled oral food challenges
Number of subjects: 113
Study: 30392239

Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg daily from day 1 to 14 of a 21-day cycle)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26432285

Group type: EXPERIMENTAL
Intervention: EVAR with intraoperative sac embolization (group B)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard EVAR (group A)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Low risk group (group C)
Number of subjects: 107
Study: 24560453

Group type: EXPERIMENTAL
Intervention: Full-spectrum endoscopy colonoscopy
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard forward-viewing colonoscopy
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 185
Study: 22266154

Group type: EXPERIMENTAL
Intervention: CVT‐E002
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study: 20457982

Group type: COMPARATOR
Intervention: No initial treatment (control group)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Exfoliation glaucoma (subgroup of patients)
Number of subjects: 118
Study: 19081383

Group type: EXPERIMENTAL
Intervention: Donepezil (cholinesterase inhibitor)
Number of subjects: 0
Study: 15939309

Group type: EXPERIMENTAL
Intervention: 1mg reproterol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 2mg DSCG
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 1mg reproterol plus 2mg DSCG
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 12859089

Group type: EXPERIMENTAL
Intervention: OptiBond Solo (total-etch technique)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V (self-etching system)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No bonding material (control group)
Number of subjects: 18
Study: 10527711

Group type: EXPERIMENTAL
Intervention: Liquid shark cartilage extract (7 ml)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Liquid shark cartilage extract (21 ml)
Number of subjects: 29
Study: 9112164

Group type: EXPERIMENTAL
Intervention: 0.05% bromocriptine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.25% timolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: timolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: timolol+bromocriptine
Number of subjects: 24

Group type: COMPARATOR
Intervention: timolol+placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: bromocriptine+placebo
Number of subjects: 24
Study: 1683840

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 9
Study: 7138750

Group type: EXPERIMENTAL
Intervention: Cimetidine (oral) for 2 months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cimetidine (intravenous infusion) for 48 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 8
Study: 29722800

Group type: COMPARATOR
Intervention: 1450 ppm fluoride toothpaste (Control group)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: 1450 ppm fluoride toothpaste plus 0.2% sodium fluoride mouth rinse
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: 5000 ppm fluoride toothpaste
Number of subjects: 255
Study: 28339993

Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide (1.0-3.0 g/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sevelamer (2.4-14.4 g/day)
Number of subjects: 84
Study: 26625755

Group type: EXPERIMENTAL
Intervention: High onion group (HO; n=28) - 100-160 g/d of fresh yellow onion for 8 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Low onion group (LO; n=28) - 30-40 g/d of small onion for 8 weeks
Number of subjects: 56
Study: 23660274

Group type: EXPERIMENTAL
Intervention: RT‐IMRT
Number of subjects: 71

Group type: COMPARATOR
Intervention: RP
Number of subjects: 71
Study: 21856592

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl (3.75 g/d)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study: 18269662

Group type: EXPERIMENTAL
Intervention: SBG mouthwash (swallowed)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SBG mouthwash (expectorated)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water rinse (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups (SBG and control)
Number of subjects: 30
Study: 17133147

Group type: EXPERIMENTAL
Intervention: Teen FreshStart Plus Buddy (TFS-B)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Teen FreshStart (TFS)
Number of subjects: 142
Study: 12969093

Group type: EXPERIMENTAL
Intervention: 200 mg ropivacaine HCl rectally in 20 mL hydroxypropyl methylcellulose gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg ropivacaine HCl rectally in 40 mL hydroxypropyl methylcellulose gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg ropivacaine HCl rectally in 60 mL hydroxypropyl methylcellulose gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg ropivacaine HCl rectally in 80 mL hydroxypropyl methylcellulose gel
Number of subjects: 12
Study: 11121911

Group type: COMPARATOR
Intervention: 7-day triple therapy based on rabeprazole (20 mg b.d.), clarithromycin (250 mg t.d.s.), and amoxicillin (500 mg t.d.s.)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 7-day triple therapy based on rabeprazole (20 mg b.d.), clarithromycin (250 mg t.d.s.), amoxicillin (500 mg t.d.s.) supplemented with a lyophilized and inactivated culture of Lactobacillus acidophilus (t.d.s.)
Number of subjects: 120
Study: 9360784

Group type: EXPERIMENTAL
Intervention: GM-CSF primed PBSC
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: GM-CSF mobilized BMSC
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: G-CSF mobilized PBSC
Number of subjects: 62

Group type: COMPARATOR
Intervention: PBSC
Number of subjects: 62

Group type: COMPARATOR
Intervention: BMSC
Number of subjects: 62

Group type: COMPARATOR
Intervention: G-CSF vs. GM-CSF
Number of subjects: 62